1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review

Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Avanir Pharmaceuticals, Inc. (Avanir) is a biopharmaceutical company. It acquires, develops and commercializes innovative therapeutic products for the treatment of central nervous system (CNS) disorders. The company’s lead product includes NUEDEXTA (AVP-923), a first-in-class dual N-methyl-D-aspartate (NMDA) rector antagonist and sigma-1 agonist. The product is approved in the US and Europe for the treatment of pseudobulbar affect (PBA). The company is also developing various products under pipeline for the treatment of CNS disorders. Avanir is headquartered in Aliso Viejo, California, the US.

In December 2014, Avanir entered into an agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir. Post acquisition, Avanir will continue to operate under its current structure as an independent subsidiary of Otsuka America, Inc.

Avanir Pharmaceuticals, Inc. Key Recent Developments

Dec 10, 2013: Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
Nov 26, 2013: Avanir Pharmaceuticals to Participate in Two Conferences in December
Nov 08, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 29, 2013: Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
Oct 23, 2013: Avanir Pharmaceuticals to Host Investor Day on October 29, 2013

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Avanir Pharmaceuticals, Inc. - Key Facts 6
Avanir Pharmaceuticals, Inc. - Key Employees 7
Avanir Pharmaceuticals, Inc. - Key Employee Biographies 8
Avanir Pharmaceuticals, Inc. - Major Products and Services 9
Avanir Pharmaceuticals, Inc. - History 10
Avanir Pharmaceuticals, Inc. - Company Statement 12
Avanir Pharmaceuticals, Inc. - Locations And Subsidiaries 14
Head Office 14
Section 2 - Company Analysis 15
Avanir Pharmaceuticals, Inc. - Business Description 15
Avanir Pharmaceuticals, Inc. - Corporate Strategy 16
Avanir Pharmaceuticals, Inc. - SWOT Analysis 17
SWOT Analysis - Overview 17
Avanir Pharmaceuticals, Inc. - Strengths 17
Strength - Sturdy Research and Development Activities 17
Strength - Strong Patent and Intellectual Property Protection 17
Avanir Pharmaceuticals, Inc. - Weaknesses 18
Weakness - History of net losses 18
Weakness - Dependence on Third-Party 18
Avanir Pharmaceuticals, Inc. - Opportunities 19
Opportunity - Changing Demographics 19
Opportunity - Product Pipeline 19
Opportunity - Market Potential - CNS Therapy 19
Avanir Pharmaceuticals, Inc. - Threats 20
Threat - Increasing Counterfeit Products 20
Threat - Product Liability Claims 20
Threat - Stringent Government Regulations 20
Avanir Pharmaceuticals, Inc. - Key Competitors 21
Section 3 - Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 23
Performance Chart 24
Financial Performance 24
Financial Ratios - Interim Ratios 25
Financial Ratios - Ratio Charts 26
Section 4 - Company's Lifesciences Financial Deals and Alliances 27
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 27
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 28
Avanir Pharmaceuticals, Inc., Recent Deals Summary 29
Section 5 - Company's Recent Developments 30
Aug 05, 2014: Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update 30
May 06, 2014: Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results 33
Mar 19, 2014: Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors 34
Feb 07, 2014: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 35
Feb 05, 2014: Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results 36
Jan 13, 2014: Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information 37
Jan 10, 2014: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 38
Jan 06, 2014: Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference 39
Section 6 - Appendix 40
Methodology 40
Ratio Definitions 40
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables

Avanir Pharmaceuticals, Inc., Key Facts 6
Avanir Pharmaceuticals, Inc., Key Employees 7
Avanir Pharmaceuticals, Inc., Key Employee Biographies 8
Avanir Pharmaceuticals, Inc., Major Products and Services 9
Avanir Pharmaceuticals, Inc., History 10
Avanir Pharmaceuticals, Inc., Key Competitors 21
Avanir Pharmaceuticals, Inc., Ratios based on current share price 22
Avanir Pharmaceuticals, Inc., Annual Ratios 23
Avanir Pharmaceuticals, Inc., Interim Ratios 25
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 27
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Type, 2009 to YTD 2015 28
Avanir Pharmaceuticals, Inc., Recent Deals Summary 29
Currency Codes 40
Capital Market Ratios 40
Equity Ratios 41
Profitability Ratios 41
Cost Ratios 42
Liquidity Ratios 42
Leverage Ratios 43
Efficiency Ratios 43

List of Figures

Avanir Pharmaceuticals, Inc., Performance Chart (2010 - 2014) 24
Avanir Pharmaceuticals, Inc., Ratio Charts 26
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 27
Avanir Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 28

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.